Last modified: January 10, 2010
Offices[edit]
People[edit]
Web Presences[edit]
- Biotech & Life Sciences
- Pharmaceutical
Industries[edit]
Parent Company[edit]
Acquisitions / Subsidiaries[edit]
Paid Sources[edit]
Keywords[edit]
|
|
Description[edit]
Osprey Pharmaceuticals USA (OPUS) is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases. The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases. The Company’s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.
The company has developed a powerful chemokine-based protein therapeutic platform based on our pioneering insight into the chemokine system, a complex network of chemokine molecules (ligands) and receptors that regulate cell migration and inflammatory immune responses. Each of our novel protein therapeutics is designed to target a specific chemokine receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
Innovation[edit]
Activities[edit]
| Jobs by SimplyHired |
- No jobs were found for this particular company. Please visit the job board to search for more.
| Osprey Pharmaceuticals USA Job Trends | Osprey Pharmaceuticals USA Jobs |
- Biotech Showcase 2010 - Presenting Companies (3 subscribers)
This Company is Being Watched in
Recent Updates |
|---|
| Osprey Pharmaceuticals USA has been added to the Ecosystem. |